文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血管内皮生长因子(VEGF)家族与免疫系统:激活剂还是抑制剂?

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?

作者信息

Failla Cristina Maria, Carbone Maria Luigia, Ramondino Carmela, Bruni Emanuele, Orecchia Angela

机构信息

Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.

Clinical Trial Center, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.

出版信息

Biomedicines. 2024 Dec 24;13(1):6. doi: 10.3390/biomedicines13010006.


DOI:10.3390/biomedicines13010006
PMID:39857591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11763294/
Abstract

The vascular endothelial growth factor (VEGF) family includes key mediators of vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and mesenchymal origin and by some immune cells in response to physiological and pathological stimuli. In addition, immune cells express VEGF receptors and/or co-receptors and can respond to VEGFs in an autocrine or paracrine manner. This immunological role of VEGFs has opened the possibility of using the VEGF inhibitors already developed to inhibit tumor angiogenesis also in combination approaches with different immunotherapies to enhance the action of effector T lymphocytes against tumor cells. This review pursues to examine the current understanding of the interplay between VEGFs and the immune system, while identifying key areas that require further evaluation.

摘要

血管内皮生长因子(VEGF)家族包括血管生成和血管新生的关键介质。VEGF由上皮和间充质来源的各种细胞以及一些免疫细胞在生理和病理刺激下分泌。此外,免疫细胞表达VEGF受体和/或共受体,并能以自分泌或旁分泌方式对VEGF作出反应。VEGF的这种免疫学作用为将已开发的VEGF抑制剂与不同免疫疗法联合使用以增强效应T淋巴细胞对肿瘤细胞的作用开辟了可能性。本综述旨在探讨目前对VEGF与免疫系统之间相互作用的理解,同时确定需要进一步评估的关键领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/3b218e4b5144/biomedicines-13-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/617b9e67f3cb/biomedicines-13-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/dd328cff3f96/biomedicines-13-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/3b218e4b5144/biomedicines-13-00006-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/617b9e67f3cb/biomedicines-13-00006-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/dd328cff3f96/biomedicines-13-00006-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7eb/11763294/3b218e4b5144/biomedicines-13-00006-g002.jpg

相似文献

[1]
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?

Biomedicines. 2024-12-24

[2]
New insights on the role of vascular endothelial growth factor in biliary pathophysiology.

JHEP Rep. 2021-2-4

[3]
Vascular endothelial growth factors and angiogenesis in eye disease.

Prog Retin Eye Res. 2003-1

[4]
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Curr Med Chem Anticancer Agents. 2003-3

[5]
[Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C].

J Soc Biol. 1999

[6]
Localization and signaling patterns of vascular endothelial growth factors and receptors in human periapical lesions.

J Endod. 2013-1-30

[7]
A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

EMBO J. 1999-1-15

[8]
Cross-family interactions of vascular endothelial growth factors and platelet-derived growth factors on the endothelial cell surface: A computational model.

bioRxiv. 2025-3-4

[9]
Vascular endothelial growth factor and its receptors.

Prog Growth Factor Res. 1994

[10]
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Proc Natl Acad Sci U S A. 2001-9-11

引用本文的文献

[1]
Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response.

Front Oncol. 2025-8-20

[2]
Macrophages in rosacea: pathogenesis and therapeutic potential.

Front Immunol. 2025-7-31

[3]
Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications.

Int J Mol Sci. 2025-4-24

[4]
Comparison of the efficacy of carbapenems and cephalosporins for postoperative treatment of perforated appendicitis in children.

World J Gastrointest Surg. 2025-4-27

本文引用的文献

[1]
Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF/VEGFR pathway.

Biomed Pharmacother. 2024-11

[2]
Integrins α5β1 and αvβ3 Differentially Participate in the Recruitment and Reprogramming of Tumor-associated Macrophages in the In Vitro and In Vivo Models of Breast Tumor.

J Immunol. 2024-11-15

[3]
Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis.

Int Ophthalmol. 2024-9-5

[4]
VEGFR1 TK signaling protects the lungs against LPS-induced injury by suppressing the activity of alveolar macrophages and enhancing the anti-inflammatory function of monocyte-derived macrophages.

Toxicol Appl Pharmacol. 2024-11

[5]
Ivonescimab: First Approval.

Drugs. 2024-9

[6]
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.

J Clin Oncol. 2024-8-1

[7]
An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.

Oral Oncol. 2024-6

[8]
Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors.

J Cancer Res Clin Oncol. 2024-4-30

[9]
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.

Angiogenesis. 2024-8

[10]
Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021-2023).

Bioorg Chem. 2024-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索